Rhumbline Advisers Grows Position in Novo Nordisk A/S (NYSE:NVO)

Rhumbline Advisers raised its stake in Novo Nordisk A/S (NYSE:NVO - Free Report) by 10.2% during the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 63,539 shares of the company's stock after acquiring an additional 5,898 shares during the period. Rhumbline Advisers' holdings in Novo Nordisk A/S were worth $4,412,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently bought and sold shares of NVO. GQG Partners LLC grew its position in shares of Novo Nordisk A/S by 74.7% during the fourth quarter. GQG Partners LLC now owns 12,994,533 shares of the company's stock valued at $1,117,790,000 after purchasing an additional 5,556,460 shares in the last quarter. Raymond James Financial Inc. bought a new position in Novo Nordisk A/S during the fourth quarter valued at approximately $404,910,000. Loomis Sayles & Co. L P raised its holdings in shares of Novo Nordisk A/S by 34.2% during the 4th quarter. Loomis Sayles & Co. L P now owns 11,571,686 shares of the company's stock worth $995,397,000 after acquiring an additional 2,947,771 shares in the last quarter. Nuveen Asset Management LLC raised its holdings in shares of Novo Nordisk A/S by 73.2% during the 4th quarter. Nuveen Asset Management LLC now owns 6,244,931 shares of the company's stock worth $537,189,000 after acquiring an additional 2,639,693 shares in the last quarter. Finally, Two Sigma Investments LP purchased a new stake in shares of Novo Nordisk A/S during the 4th quarter worth approximately $158,657,000. 11.54% of the stock is currently owned by institutional investors.

Novo Nordisk A/S Stock Down 1.4%

Shares of NYSE NVO opened at $79.90 on Friday. The company has a market cap of $358.57 billion, a P/E ratio of 24.29, a PEG ratio of 0.90 and a beta of 0.66. The firm has a 50-day simple moving average of $67.30 and a two-hundred day simple moving average of $79.82. Novo Nordisk A/S has a 1 year low of $57.00 and a 1 year high of $148.15. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.74 and a quick ratio of 0.55.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last issued its earnings results on Wednesday, May 7th. The company reported $0.92 EPS for the quarter, hitting analysts' consensus estimates of $0.92. The business had revenue of $11.87 billion for the quarter. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. Research analysts anticipate that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Analyst Upgrades and Downgrades

NVO has been the topic of several research reports. BMO Capital Markets restated a "market perform" rating and issued a $64.00 price target (down previously from $105.00) on shares of Novo Nordisk A/S in a research report on Thursday, April 17th. Guggenheim cut shares of Novo Nordisk A/S from a "strong-buy" rating to a "hold" rating in a research note on Thursday, April 17th. BNP Paribas started coverage on shares of Novo Nordisk A/S in a report on Tuesday, April 15th. They issued an "underperform" rating for the company. Kepler Capital Markets upgraded Novo Nordisk A/S from a "hold" rating to a "buy" rating in a research report on Thursday, March 13th. Finally, Wall Street Zen upgraded Novo Nordisk A/S from a "hold" rating to a "buy" rating in a research report on Saturday. Two analysts have rated the stock with a sell rating, five have given a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Hold" and an average target price of $112.00.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.

Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.